| Revenue growth | 12% QoQ growth to ₹342cr; base business at multi-quarter highs. |
|---|---|
| Margins | Consolidated EBITDA 16%; base business at 26%, Ibuprofen remains negative. |
| Order book | Healthy order book driven by base business and customer wallet share. |
| Demand visibility | Strong order book in base business; focus on new geographies. |
| Management confidence | Balanced; optimistic on base business but cautious on Ibuprofen legacy issues. |
Growth
12% QoQ revenue growth; base business margins at 26% EBITDA. Growth is structurally driven by customer base expansion.
Outlook
Targeting debt reduction to sub-₹503cr by end-May 2026; filing 4-5 new DMFs annually starting FY26.
Risks
Persistent Ibuprofen headwinds causing negative EBITDA; strategic review of Ibuprofen/Vizag assets creates medium-term uncertainty.
Earnings Call filed with NSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹685.00
- Market cap
- ₹3,292 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2032.1×Sector 47.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Legal & Regulatory
Solara Active Pharma Sciences Limited received a rectification order dropping an earlier income tax demand of Rs. 161.92 Crore. The demand was reduced to nil.
- Value
- ₹161.9 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This is a periodic regulatory compliance disclosure.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited has issued the notice for its Ninth Annual General Meeting, scheduled to be held on September 18, 2026.
Solara Active Pharma Sciences Capital Structure Change
Solara Active Pharma Sciences approved the conversion of 2,79,582 partly paid-up rights shares into fully paid-up equity. The conversion followed receipt of pending first and final call monies.
- Value
- ₹3.89 Cr